PABPC1: A promising drug target and biomarker for the treatment of parseminer-associated breast cancer

Target Name: PABPC1

NCBI ID: G26986

PABPC1

PABPC1: A promising drug target and biomarker for the treatment of parseminer-associated breast cancer

Abstract:

Breast cancer is a leading cause of cancer-related deaths worldwide, with high incidences of both node-positive and node-negative cases. Despite advances in the treatment of breast cancer, the survival rates for node-negative patients remain poor. Therefore, there is a need for new and effective drug targets and biomarkers to improve the treatment outcomes for breast cancer patients. PABPC1, a gene encoding a protein known as protamineuronuclease (PAN), has been identified as a potential drug target and biomarker for the treatment of parseminer -associated breast cancer (PABPC). This article reviews the current literature on PABPC1, including its expression and role in breast cancer progression, as well as its potential as a drug target and biomarker.

Introduction:

Breast cancer is a heterogeneous disease, with different subtypes and subgroups of tumors. One of the most aggressive subtypes of breast cancer is parseminer-associated breast cancer (PABPC), which accounts for approximately 10% of all breast cancers. PABPC tumors are characterized by the presence of the protein Parcminer, a transcription factor that plays a role in the development and progression of breast cancer. In addition to Parcminer, PABPC tumors also express the gene PABPC1, which encodes a protein known as protamineuronuclease (PAN).

The Role of PABPC1 in Breast Cancer Progression:

PABPC1 is a key regulator of cell proliferation and survival in breast cancer. It has been shown to promote the growth and survival of breast cancer cells, and has been involved in the development of resistance to chemotherapy in these cells. In addition, PABPC1 has also has been shown to promote the angiogenesis (the formation of new blood vessels) in breast cancer, which contributes to tumor growth and the development of metastasis.

Potential Role of PABPC1 as a Drug Target:

PABPC1 is a potential drug target for the treatment of breast cancer due to its involvement in cell proliferation and survival. Drugs that target PABPC1 have been shown to be effective in both preclinical and clinical settings in the treatment of breast cancer. For example, inhibitors of the protein phosphorylase-3 (PPI) have been shown to be effective in the treatment of PABPC1-positive breast cancer. Additionally, inhibitors of PABPC1 itself have also been shown to be effective in preclinical studies.

Potential Role of PABPC1 as a Biomarker:

PABPC1 has also been identified as a potential biomarker for the treatment of breast cancer. Its expression has been shown to be associated with the outcomes of several breast cancer clinical trials, including those for the treatment of node-negative breast cancer. Additionally, changes in PABPC1 expression have also been identified as potential biomarkers for the diagnosis and prognosis of breast cancer.

Conclusion:

PABPC1 is a promising drug target and biomarker for the treatment of parseminer-associated breast cancer. Its involvement in cell proliferation and survival makes it a potential target for small molecule inhibitors. Additionally, its potential as a biomarker for the diagnosis and prognosis of breast cancer makes it an attractive candidate for clinical use. Further research is needed to fully understand the role of PABPC1 in breast cancer and its potential as a drug target and biomarker.

Keywords: PABPC1, Parcminer, Protamineuronuclease, Breast cancer, Node-negative, Small molecule inhibitors, Biomarker, Drug target

Protein Name: Poly(A) Binding Protein Cytoplasmic 1

Functions: Binds the poly(A) tail of mRNA, including that of its own transcript, and regulates processes of mRNA metabolism such as pre-mRNA splicing and mRNA stability (PubMed:11051545, PubMed:17212783, PubMed:25480299). Its function in translational initiation regulation can either be enhanced by PAIP1 or repressed by PAIP2 (PubMed:11051545, PubMed:20573744). Can probably bind to cytoplasmic RNA sequences other than poly(A) in vivo. Binds to N6-methyladenosine (m6A)-containing mRNAs and contributes to MYC stability by binding to m6A-containing MYC mRNAs (PubMed:32245947). Involved in translationally coupled mRNA turnover (PubMed:11051545). Implicated with other RNA-binding proteins in the cytoplasmic deadenylation/translational and decay interplay of the FOS mRNA mediated by the major coding-region determinant of instability (mCRD) domain (PubMed:11051545). Involved in regulation of nonsense-mediated decay (NMD) of mRNAs containing premature stop codons; for the recognition of premature termination codons (PTC) and initiation of NMD a competitive interaction between UPF1 and PABPC1 with the ribosome-bound release factors is proposed (PubMed:18447585). By binding to long poly(A) tails, may protect them from uridylation by ZCCHC6/ZCCHC11 and hence contribute to mRNA stability (PubMed:25480299)

The "PABPC1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PABPC1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets